Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Nov 25, 2019 (7 years ago)

Petroleum jelly

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Cross contamination with other products: undeclared contaminants of phenol and camphor in petroleum jelly tubes.

Cause type: Cross-contamination

Traces of another drug - most often penicillin - got into the product from shared equipment or facilities. Even trace penicillin can trigger a severe allergic reaction in someone who was never meant to receive it. All cross-contamination recalls.

What was recalled

Petroleum jelly (White Petrolatum) USP 100%, packaged in a) 1 oz tube (UPC 1182298884), b) 2.5 oz tube (UPC 1182298541), Distributed by Rite Aid, 30 Hunter Lane, Camp Hill, PA 17011

Recalling firm
OraLabs, Incorporated
Origin
CO, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0624-2020 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other cross-contamination recalls from 2019

All cross-contamination recalls
Class I · High risk

Lamotrigine Tablets

Cross Contamination; Lamotrigine Tablets 100 mg USP was contaminated with enalapril maleate.

Terminated Cross-contamination Taro Pharmaceuticals U.S.A., Inc. NDC 51672-4131-1 D-0833-2020
Class II · Moderate risk

Temozolomide Capsules

CGMP Deviations: product was manufactured that did not prevent possible cross contamination with beta lactam products.

Terminated Cross-contamination Deva Holding AS - Cerkezkoy Subesi NDC 67877-542-07 D-1513-2019
Class II · Moderate risk

Temozolomide Capsules

CGMP Deviations: product was manufactured that did not prevent possible cross contamination with beta lactam products.

Terminated Cross-contamination Deva Holding AS - Cerkezkoy Subesi NDC 67877-541-07 D-1512-2019
Class II · Moderate risk

Temozolomide Capsules

CGMP Deviations: product was manufactured that did not prevent possible cross contamination with beta lactam products.

Terminated Cross-contamination Deva Holding AS - Cerkezkoy Subesi NDC 67877-540-07 D-1511-2019